Side-by-side · Research reference

AdipotidevsThymalin

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED15/49 cited

BHuman-MechanisticAUTO-DRAFTED12/40 cited

Adipotide

Pro-apoptotic Vascular-Targeting Peptide · Preclinical Only

PreclinicalStatus

PHB1TargetHossen 2013

ApoptosisMechanismHossen 2013

IV · Systemic · Preclinical Protocols OnlyHossen 2013

Thymalin

Immune restorer · Russian peptide bioregulator

5–10 mgPer cycle doseKhavinson 2002

HumanMechanisticKhavinson 2002

HoursHalf-life (est)

IM · Daily for 5–10 days · 1-2×/year

01Mechanism of Action

Parameter

Adipotide

Thymalin

Primary target

Prohibitin-1 (PHB1) on adipose vasculature endotheliumHossen 2013

T-cell precursors + thymus-axis maturation pathwayKhavinson 2002

Pathway

CKGGRAKDC domain binds PHB1 → Peptide internalisation → D(KLAKLAK)₂ mitochondrial membrane disruption

Modulation of T-cell differentiation + thymic hormone restoration in age-involuted thymusKhavinson 2002

Downstream effect

Endothelial apoptosis → Adipose vascular collapse → Adipocyte involution → Weight loss

Restored T-cell populations, improved immune surveillance, reduced infection rates in elderlyKhavinson 2002

Feedback intact?

N/A — Direct apoptotic mechanism, non-hormonal

—

Origin

Synthetic bioconjugate: PHB1-targeting homing peptide + pro-apoptotic KLA sequence

Polypeptide fraction isolated from calf thymus extractKhavinson 2002

Antibody development

—

02Dosage Protocols

Parameter

Adipotide

Thymalin

Animal dose (mouse)

Low dose (not specified in abstract)Hossen 2013

Systemic injection in diet-induced obesity (DIO) models.Hossen 2013

—

Route

Intravenous (systemic injection)

—

Frequency

Not specified in available data

Once daily during cycle

Evidence basis

Preclinical animal models only

Russian clinical + in vitroKhavinson 2002

Human data

None — no clinical trials reported

—

Standard dose

—

5–10 mg / day IM × 5–10 daysKhavinson 2002

Lower / starter dose

—

2.5 mg / day

Duration

—

5–10 day cycles, 1–2× per year

Reconstitution

—

Saline or bacteriostatic water

Timing

—

Morning preferred

Half-life

—

Hours (estimated)

03Metabolic / Fat Loss Evidence

Parameter

Adipotide

Thymalin

Primary fat target

White adipose tissue (all depots)

—

Mechanism

Vascular apoptosis → adipose blood supply collapse → adipocyte deathHossen 2013

—

Body weight reduction

Significant reduction in DIO miceHossen 2013

Absolute values not provided in abstract.

—

Leptin levels

Significant decrease

Parallel to adipose mass reduction.

—

Effect on adipocytes

Antiobesity effect on dysfunctional adipose cells (adipocytes + macrophages)Hossen 2013

—

Ectopic fat

Reduction in ectopic fat depositionHossen 2013

Marker of dysfunctional adipose tissue / metabolic syndrome.

—

Species tested

Obese rhesus monkeys, DIO mice

—

Human translation

Unknown — no clinical trials

—

04Side Effects & Safety

Parameter

Adipotide

Thymalin

Safety profile

Unknown — preclinical data only

—

Vascular selectivity

Targets adipose vasculature; off-target vascular effects unknown

—

Apoptotic mechanism risk

Pro-apoptotic payload may affect unintended tissues if selectivity incomplete

—

Kidney / liver toxicity

Not reported in available data

—

Immunogenicity

Not assessed in available data

—

Injection site reaction

—

Mild erythema at IM site

Allergic reaction

—

Rare hypersensitivity to bovine-derived polypeptide

Autoimmune flare

—

Theoretical risk in active autoimmune disease

Long-term safety

—

Limited Western data

Pregnancy / OB

—

Avoid

Absolute Contraindications

Adipotide

·Human use — not approved, no clinical safety data

Thymalin

·Pregnancy / breastfeeding
·Bovine protein hypersensitivity

Relative Contraindications

Adipotide

·Any condition requiring intact adipose-tissue vascularisation

Thymalin

·Active autoimmune disease
·Concurrent immunosuppressant therapy

05Administration Protocol

Parameter

Adipotide

Thymalin

1. Route

Intravenous injection (systemic) in preclinical models. No human protocols exist.

Add 1–2 mL saline or bacteriostatic water per 10 mg vial.

2. Formulation

Bioconjugate peptide. May also be encapsulated in nanoparticles (prohibitin-targeted nanoparticle formulation, KLA-PTNP, showed superior efficacy vs. free bioconjugate in mice).Hossen 2013

Intramuscular — deltoid or gluteal. Rotate sites.

3. Preclinical dosing

Low-dose systemic injection (exact dosing not specified in available abstract). Frequency and duration not detailed.Hossen 2013

Morning preferred during cycle.

4. Storage

Not specified — likely requires peptide-grade lyophilised storage and reconstitution.

Lyophilised: refrigerate, light-protected. Reconstituted: use immediately.

5. Needle

—

23–25G, 25–38 mm IM needle.

06Stack Synergy

Adipotide

— no documented stacks

Thymalin

+ Thymosin α-1

Moderate

View Thymosin α-1 →

Thymalin is a polypeptide complex; Thymosin α-1 is a single purified peptide. Both target the thymus-axis but at different levels — Thymalin restores broad thymic signaling; Tα-1 provides a specific molecular activator. Anecdotally combined for elderly immune support.

Thymalin: 5–10 mg IM · daily × 7 days
Thymosin α-1: 1.6 mg SQ · 2× weekly during the cycle
Primary benefit: Broad thymic restoration + targeted immune activation

Khavinson 2002 Camerini 2001